Metocard Zk

Metoprolol Tartrate, the active ingredient in Metocard Zk, is a beta blocker presented as an oral dosage form for oral use. It is employed to lower high blood pressure, relieve chest pain from angina, improve outcomes after a heart attack, and manage certain types of heart failure in adult patients.

GNH USA supplies Metocard Zk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides regulatory documentation for global distribution.

Metocard Zk (metoprolol tartrate) is indicated for several cardiovascular conditions that involve elevated sympathetic activity.

- Hypertension: reduces systolic and diastolic blood pressure, helping to prevent stroke and renal complications. - Chronic stable angina: decreases myocardial oxygen demand, relieving chest pain during exertion. - Post‑myocardial infarction: lowers the risk of recurrent infarction and improves survival. - Heart failure: improves left‑ventricular function and reduces hospitalization rates.

Metocard Zk may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness, especially when standing - Cold extremities such as hands and feet - Gastrointestinal discomfort, including nausea or abdominal pain

Serious or Rare Side Effects: - Bradycardia (abnormally low heart rate) - Severe bronchospasm in patients with underlying airway disease

Before prescribing Metocard Zk, clinicians should consider several precautionary measures to ensure safe use.

- Assess baseline heart rate and blood pressure: avoid initiation in patients with bradycardia or hypotension. - Review respiratory history: use cautiously in asthma or chronic obstructive pulmonary disease. - Monitor renal and hepatic function: dose adjustments may be required in impairment. - Evaluate for diabetes: beta‑blockade can mask hypoglycaemic symptoms. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Metocard Zk can interact with other medicines, altering its effectiveness or increasing risk of adverse events.

Major Interactions (Avoid): - Concomitant use with non‑selective beta blockers or calcium‑channel blockers such as verapamil: may cause excessive bradycardia or heart block. - Combined therapy with potent CYP2D6 inhibitors (e.g., quinidine, paroxetine): can raise metoprolol plasma concentrations and precipitate toxicity.

Moderate Interactions (Monitor Closely): - Concurrent use of antidiabetic agents: beta‑blockade may mask hypoglycaemia signs, requiring glucose monitoring. - Co‑administration with other antihypertensives (e.g., ACE inhibitors, diuretics): may enhance blood pressure lowering, necessitating dose titration.